All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA approves the Investigational New Drug Application for PCM-075 for the treatment of AML

By Cynthia Umukoro

Share:

Jul 31, 2017


On 27th July 2017, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for PCM-075, a Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of Relapsed or Refractory (R/R) patients with Acute Myeloid Leukemia (AML).1

In most normal tissues, PLK1 is expressed at very low levels, however it has been found to be overexpressed in multiple AML cell lines and also in leukemia blasts from AML patients. Overexpression of PLK1 in AML patients have been reported to be associated with poor prognosis in these group of patients.2 PCM-075 selectively inhibits the PLK1 enzyme thereby inducing cell cycle arrest and apoptosis in cancer cells.3

The IND approval granted by the FDA allows PCM-075 to be evaluated in a phase Ib/II clinical trial which aims to evaluate the safety and efficacy of PCM-075 in combination with decitabine in patients with AML, who are in relapse or refractory.

References